Related Experiment Video
Updated: May 11, 2026
11:49
Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
Which patients with sentinel node-positive breast cancer can avoid axillary dissection?
1From the Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY; Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
Summary
Sentinel lymph node biopsy is standard for early breast cancer. Many patients with positive sentinel lymph nodes may not need further axillary dissection, reducing treatment morbidity.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Cancer Management
Background:
- Sentinel lymph node (SLN) biopsy is the standard for staging axillary lymph nodes in cN0 breast cancer.
- Established evidence shows negative SLN biopsy obviates the need for axillary lymph node dissection (ALND).
- Growing data suggests ALND may be safely omitted in selected patients with positive SLN.
Purpose of the Study:
- To review the current evidence regarding the role of axillary lymph node dissection (ALND) in breast cancer management.
- To evaluate the diminishing role of ALND in favor of sentinel lymph node biopsy (SLN).
- To identify patient subgroups who may not require ALND even with positive SLN findings.
Main Methods:
- Comprehensive literature review, including randomized trials and observational studies.
- Analysis of data from key trials like ACOSOG Z0011.
- Evaluation of outcomes for patients undergoing SLN biopsy with and without ALND.
Main Results:
- Extensive literature confirms negative SLN biopsy negates the need for ALND, with rare local recurrence and unaffected survival.
- The ACOSOG Z0011 trial demonstrated equivalent outcomes with or without ALND in specific breast cancer patients.
- Emerging data supports omitting ALND in selected cases treated with mastectomy, partial breast irradiation, or neoadjuvant chemotherapy.
Conclusions:
- Sentinel lymph node biopsy is sufficient for axillary staging, prognostication, and local control in most breast cancer patients.
- The necessity of axillary lymph node dissection is significantly decreasing.
- Future breast cancer management will likely rely primarily on SLN biopsy, minimizing the role of ALND.
